Thursday, 14 Nov 2019

You are here

Are Non-TNF Biologics Superior to TNF inhibitors?

Current ACR and EULAR guidelines list TNF-inhibitors (TNFi) abatacept, rituximab, and tocilizumab as being equally effective after methotrexate or as second line therapies when treating rheumatoid arthritis. An analysis from the Swedish Rheumatology Register shows that the non-TNFi biologic DMARDs (bDMARDs), in particular tocilizumab and rituximab, are more effective than TNFi. 

RA patients in this registry were included if they initiated TNFi, rituximab, abatacept or tocilizumab between 2010–2016 as first bDMARD (n = 9333), or after switch from TNFi as first bDMARD (n = 3941).

Effectiveness was assessed 3 and 12 months based on the proportion remaining on therapy and with EULAR Good Response, HAQ improvement >0.2, zero swollen/tender joints and CDAI remission.

At 1 year, patients starting non-TNFi (vs TNFi) as first bDMARD had a higher proportion remaining on drug and reaching most response outcomes as first bDMARD (EULAR Good Response/HAQ improvement):

  • TNFi 24.9/25.4%
  • Rituximab 28.6/37.2%
  • Abatacept 31.9/33.7%
  • Tocilizumab 50.9/43.1%).

After switch from a first TNFi, rituximab and tocilizumab, but not abatacept, were associated with significantly better response measures than continuing TNFi (1-year EULAR Good Response/HAQ improvement):

  • TNFi 11.6/16.1%
  • Rituximab 24.8/33.2%
  • Abatacept 13.1/17.5%
  • Tocilizumab 34.1/29.4%)

While guidelines are based on metanalyses and expert consensus (and not head-to-head trials), these real world data suggest high efficacy when using non-TNFi bDMARDs, in particular tocilizumab and rituximab, as either the first bDMARD or as a switch candidate after TNFi.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

New EMA Warnings for Tofacitinib in Patients at Risk for Clots

The European Medicines Agency safety committee (PRAC) has concluded that Xeljanz (tofacitinib - TOFA) could increase the risk of blood clots in the lungs and in deep veins in patients who are already at high risk for venous thromboembolic events. The PRAC is recommending that TOFA should be used with caution in patients at high risk of blood clots (VTE), regardless of dose used.

FDA Approves Ustekinumab for Ulcerative Colitis

Ustekinumab (Stelara) is now FDA-approved to treat moderately to severely active ulcerative colitis, said drugmaker Janssen on Monday, in addition to its indications for psoriasis, psoriatic arthritis, and Crohn's disease.

Interleukin Targeted Biologics Increase Risks of Infection

A systematic review of the literature shows that, compared to placebo, the use of non-TNF, interleukin inhibitor biologics may be associated with significantly higher rates of serious infections, opportunistic infections, and cancer.

Biologics Lead the Way in Drug Price Increases

Reuters has reported the results of a recent Institute for Clinical and Economic Review (ICER) analysis showing that biologics, especially Humira and Rituxan, are leading the way in the cost of drugs in the USA. All told, Humira and Rituxan topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. drug spending. ICER said their analysis points to price hikes that were more than twice the rate of medical inflation and were not warranted by any new clinical evidence.

Ustekinumab Efficacy in Ulcerative Colitis

The NEJM reports the results of a one year trial wherein ustekinumab (UST) was shown to be effective at inducing and maintaining remission in patients with moderate-to-severe ulcerative colitis. Ustekinumab, currently approved for use in psoriasis, psoriatic arthritis and Crohn's disease, is a monoclonal antibody against the p40 subunit of interleukin-12 and interleukin-23.